


Data Sheet (Cat.No.T16274)

Narlaprevir

Chemical Properties

CAS No.:	865466-24-6
Formula:	C ₃₆ H ₆₁ N ₅ O ₇ S
Molecular Weight:	707.96
Appearance:	N/A
Storage:	0-4°C for short term (days to weeks), or -20°C for long term (months).



Biological Description

Description	Narlaprevir is an effective, selective, and orally bioavailable NS3 protease inhibitor(Ki=6 nM; EC90=40 nM).
Targets(IC ₅₀)	Others: None
In vitro	Narlaprevir administration resulted in a robust HCV-RNA decline and high SVR rates when followed by standard of care in both treatment-experienced and treatment-naive HCV genotype 1-infected patients. HCV Narlaprevir is a potent inhibitor of the hepatitis C virus (HCV) nonstructural protein 3 serine protease that is primarily metabolized by the cytochrome P450-3A4 system.

Solubility Information

Solubility	DMSO: 50 mg/mL (70.63 mM) (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	---

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.413 mL	7.063 mL	14.125 mL
5 mM	0.283 mL	1.413 mL	2.825 mL
10 mM	0.141 mL	0.706 mL	1.413 mL
50 mM	0.028 mL	0.141 mL	0.283 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. The storage conditions and period of the stock solution: - 80 °C for 6 months; - 20 °C for 1 month. Please use it as soon as possible.

Reference

1. Ashok Arasappan, et al. Discovery of Narlaprevir (SCH 900518): A Potent, Second Generation HCV NS3 Serine Protease Inhibitor. ACS Med. Chem. Lett., 2010, 1 (2), pp 64–69
2. Tong X, Arasappan A, Bennett F, Chase R, Feld B, Guo Z, Hart A, Madison V, Malcolm B, Pichardo J, Prongay A, Ralston R, Skelton A, Xia E, Zhang R, Njoroge FG. Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease. Antimicrob Agents Chemother. 2010 Jun;54(6):2365-70. Epub 2010 Mar 22.
3. Zhu J, Li Y, Yu H, Zhang L, Mao X, Hou T. Insight into the structural requirements of narlaprevir-type inhibitors of NS3/NS4A protease based on HQSAR and molecular field analyses. Comb Chem High Throughput Screen. 2012 Jul;15(6):439-50.
4. de Bruijne J, Bergmann JF, Reesink HW, Weegink CJ, Molenkamp R, Schinkel J, Tong X, Li J, Treitel MA, Hughes EA, van Lier JJ, van Vliet AA, Janssen HL, de Kneegt RJ. Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients. Hepatology. 2010 Nov;52(5):1590-9.
5. Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2010 Nov;32(9):675-703.

Inhibitors · Natural Compounds · Compound Libraries

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use.

Tel: 781-999-4286

E-mail: info@targetmol.com

Address: 36 Washington Street, Wellesley Hills, MA 02481